Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104

- January 25th, 2019

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a licensing and supply agreement for ET-104, an innovative oral liquid product candidate for the treatment of a neurological condition. As quoted in the press release: ET-104’s active ingredient is approved and marketed … Continued

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a licensing and supply agreement for ET-104, an innovative oral liquid product candidate for the treatment of a neurological condition.

As quoted in the press release:

ET-104’s active ingredient is approved and marketed in an oral solid formulation, but the active ingredient is not approved by the U.S. Food and Drug Administration (FDA) in liquid form. Presently, patients requiring liquid formulations of the active ingredient are reliant on compounded products. ET-104 is expected to address this significant unmet patient need and will be Eton’s third neurology-focused product in its pipeline. Eton’s partner plans to file a patent on its unique formula in the first quarter of 2019.

Eton and its partner, Liqmeds Worldwide Limited, a United Kingdom-based pharmaceutical development and manufacturing company, expect to complete a bioequivalence trial in the second half of 2019 and, if successful, expect to file a New Drug Application with the FDA by the end of 2019.

“With over 100 million pills prescribed annually for ET-104’s active ingredient, we believe there is a significant opportunity to bring a liquid formulation to patients who are unable to swallow pills,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “We are eager to add ET-104 to our growing pipeline and we expect to continue to actively pursue additional opportunities to add late-stage assets to our portfolio.”

Click here to read the full press release.

 

Investing During the Pandemic

   
The latest on what experts see coming for resources and commodities amidst the Coronavirus pandemic.
 

Leave a Reply